The investigators analyzed 1,600 patients drawn from the STRATS-HHD registry who received echocardiography at baseline and again between 6 and 18 months after treatment initiation. The team defined cardiovascular-kidney-metabolic (CKM) burden as the presence of four discrete components: obesity, diabetes, chronic kidney disease, and severe hypertension. Patients were stratified into three groups by CKM component count: 0–1, 2, or ≥3. Distribution in the cohort was reported as 973 patients (60.8%) with 0–1 components, 440 (27.5%) with two, and 187 (11.7%) with three or four components. The primary study outcome combined cardiovascular death and heart failure hospitalization (HHF).
Data indicated that higher CKM burden correlated with worse baseline cardiac structure and function. The cohort with ≥3 CKM components showed the most pronounced echocardiographic abnormalities at baseline, investigators reported. Risk modelling demonstrated a graded relationship between CKM burden and adverse events: compared with patients with 0–1 components, those with ≥3 components had an adjusted hazard ratio of 3.09 (95% CI, 1.92–4.98) for the primary outcome. The authors also reported an adjusted HR of 1.53 (95% CI, 1.27–1.84) per additional CKM component, reflecting incremental prognostic weight for each component present.
The prognostic association remained after additional adjustment for metabolic liver disease categorized by hepatic steatosis index, the study team observed. That adjustment suggests the CKM burden signal was not entirely explained by concurrent hepatic steatosis as defined in their dataset.
Overall, most echocardiographic parameters improved after treatment across the cohort. Short-term remodeling occurred following therapeutic initiation, and several measures showed favorable change at 6–18 months. Despite this general improvement, the investigators found that patients with CKM burden ≥3 had less favorable recovery in key functional measures at follow-up. Specifically, E/e′, LV global longitudinal strain (GLS), and left atrial (LA) stiffness index remained worse in the high-burden group compared with lower-burden groups.
The study team noted that normalization of those echocardiographic parameters at follow-up — when achieved — associated with substantially lower subsequent cardiovascular risk. The implication reported was that failure to normalize select functional indices after treatment identifies a subgroup at continued elevated risk for cardiovascular death or HHF.
Investigators performed mediation analyses to explore how much of the CKM burden–outcome relationship could be attributed to echocardiographic abnormalities. The analyses suggested that persistent structural and functional echocardiographic changes partially mediated the association between high CKM burden and the primary outcome. In other words, the pathway from CKM burden to events appeared to be, at least in part, through less favorable cardiac remodeling and incomplete functional recovery after treatment.
Those findings link a clinical multimorbidity construct — CKM burden — with measurable changes on imaging that have independent prognostic meaning. The authors reported that these imaging markers, when normalized, identified patients with markedly lower subsequent event risk, supporting their potential role as intermediate endpoints in risk stratification.
This work used a retrospective registry design; the authors obtained institutional review board approvals and a waiver of informed consent was documented given the retrospective nature. The source did not report randomized allocation, specific antihypertensive regimens, dosing details, or the exact interventions used between baseline and follow-up echocardiography. The dataset is available from the corresponding author on reasonable request, as stated in the manuscript.
The study team acknowledged mediation analyses indicated only partial mediation, leaving unanswered the magnitude of effect attributable to unmeasured biological or treatment-related factors. The source did not report subgroup analyses by individual CKM components beyond the composite burden categories, nor did it provide granular time-to-event curve data or prespecified thresholds for echocardiographic “normalization.” These gaps limit direct translation to protocolized clinical decisions.
Future work should clarify which therapeutic strategies most effectively reverse the specific echocardiographic abnormalities observed in high CKM burden patients, and whether targeted interventions alter the excess cardiovascular risk documented here. The manuscript concludes with these concrete limitations and the availability of data upon request, rather than broader speculative statements.